AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05807009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core exercise
Description: the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.
Study NCT05807009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
Study NCT04911621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination + temozolomide-based chemoradiation
Description: 1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle.
Study NCT04911621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination +- conventional next-line treatment
Description: 1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition.
Study NCT05763602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone-iodine topical ointment
Description: Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
Study NCT04917926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial and social incentives
Description: Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
Study NCT04917926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
Study NCT05555004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST1
Description: Toddler milk with preconditioned L. reuteri and containing GOS
Study NCT05555004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST 2
Description: Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
Study NCT05495347 — intervention group
Intervention type: OTHER
Intervention: patients diagnosed with OSA
Description: All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
Study NCT04840121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AdhesioRT
Description: AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
Study NCT05015309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH3765 tablet
Description: Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
Study NCT06199167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
Study NCT06199167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo Observation
Description: The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
Study NCT04831632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: quantitative and qualitative iFOBTs
Description: They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
Study NCT06052956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
Study NCT06052956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Emulsion
Description: The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
Study NCT06052956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of optical fiber
Description: A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
Study NCT06052956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Illumination (pre-defined dose)
Description: Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
Study NCT06052956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Spectroscopy Measurement
Description: The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
Study NCT06052956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Illumination (patient-specific dose)
Description: Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
Study NCT06052956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care abscess drainage
Description: Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
Study NCT06052956 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care abscess drainage
Description: Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
Study NCT05568771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Exercises Assisted Injury Prevention Training Program
Description: After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
Study NCT05300087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Inhalation Aerosol 108mcg per actuation
Description: MDI, 2 puffs, single dose, fasting
Study NCT05300087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation
Description: MDI, 2 puffs, single dose, fasting
Study NCT05790486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a Break plus Nicotine replacement therapy (NRT) Sampling
Description: Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal.
Study NCT05790486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Comparison
Description: The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
Study NCT05790486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Paramedicine Standard Plus Enhanced Implementation Program
Description: Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
Study NCT05790486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Paramedicine Standard Implementation Program
Description: In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
Study NCT06294600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Oral tablets of 500mg of clarithromycin
Study NCT06294600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tablets
Description: Oral tablets of similar appearance to active study drug
Study NCT05782647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartGuide cuffless BP monitor
Description: Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
Study NCT05786157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
Study NCT04640714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONTINUity of care Under Management by Video visits (CONTINUUM-V)
Description: Video visit by nurse practitioner within 3 business days of hospital discharge.
Study NCT05192343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality and nature sounds
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video.
Study NCT05192343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature sounds
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes.
Study NCT05313438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPNS Therapy
Description: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
Study NCT05782647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartGuide cuffless BP monitor
Description: Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
Study NCT05284201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFT System
Description: The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
Study NCT05173584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
Study NCT05173584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
Study NCT06343090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell
Description: Murine-derived CD19 CAR T cells
Study NCT06343090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR T cells
Description: humanized CD22 CAR T cells
Study NCT06343090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem-cell transplantation
Description: allo-HSCT
Study NCT05117918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUFU Clinical Care Pathway for Overactive Bladder
Description: Treatment of OAB via the SUFU clinical care pathway
Study NCT05117918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SUFU Clinical Care Pathway for Overactive Bladder
Description: Treatment of OAB via the SUFU clinical care pathway
Study NCT05117918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Delivery of care via telemedicine
Study NCT04668261 — intervention group
Intervention type: OTHER
Intervention: Advanced imaging investigation
Description: MRI imaging
Study NCT04678687 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver, lung, heart and kidney biopsy
Description: Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
Study NCT05383924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postplacental IUD insertion
Description: patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD.
Study NCT05383924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed IUD insertion
Description: cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
Study NCT05213273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional guidelines to promote healthy diet and increase fish intake
Description: Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish.
Study NCT06154902 — intervention group
Intervention type: DRUG
Intervention: Idecabtagene vicleucel
Description: According to approved product label in France
Study NCT06154902 — intervention group
Intervention type: OTHER
Intervention: Not treated
Description: Eligible for idecabtagene vicleucel treatment but not treated
Study NCT06002230 — intervention group
Intervention type: DRUG
Intervention: Homeopathic medicines
Description: Globules were administered orally..
Study NCT06544109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
Study NCT05567965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home care intervention
Description: The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
Study NCT05567965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home care intervention
Description: The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
Study NCT05531422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled fentanyl aerosol
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Study NCT05531422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Study NCT05380024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225mg QD 8 weeks
Study NCT04704505 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radium-223
Description: Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,